About Event

Uniting KOLs, industry experts and regulators at the forefront of kidney disease research, the 6th CKD Drug Development Summit was biopharma’s must-attend forum for staying up to date with the latest breakthroughs in surrogate endpoint innovation, novel pathway and target exploration, the advancement of personalized therapies, and much more.

What was new in 2024:

  • 60+ Brand New Speakers: Participants Broadened their network of industry peers working across diabetic, hypertensive and rare kidney disease with fresh faces brining novel insights from the likes of Regeneron, HI-Bio, GSK, Novo Nordisk, Eli Lilly and Vertex Pharmaceuticals
  • The First IgA Nephropathy Seminar Day: Deepen understanding of pathophysiology and genetic architecture to explore new targets, participants discovered the latest complement, APRIL and BlyS clinical data, and discussed the integration of emerging IgAN treatments into evolving care standards with Calliditas, Otsuka, Novartis, Genentech, Takeda, Vera Therapeutics, Alexion and more.
  • Three Dedicated Tracks of Content: Teams attended highly focused discussions on three distinct areas: target discovery and preclinical CKD models, exploratory biomarkers and early clinical innovation, and regulatory-accepted clinical endpoints and outcomes research.

Highlights of 2024

Navigating complex heterogeneity in CKD populations to identify more precise targets with Novo Nordisk, Regeneron and Maze Therapeutics, and discovering more human-relevant in vivo, ex vivo and in vitro kidney models to streamline translational progress with Pfizer, Eli Lilly, and Janssen

Examining recent progress to understand how proteinuria and GFR slope can strengthen implications of clinical benefit and validating the relevance of these surrogates in FSGS, Lupus Nephritis, PKD and more with Hiddo Heerspink, Bayer, AstraZenecaNephCure, and the EMA

Advancing exploratory biomarkers and proof-of-concept studies with Alpine Immune Sciences, C-Path and HI-Bio and evaluating the clinical potential of immunomodulatory candidates for CKD and renal transplantation with Novartis, Visterra, and Alexion

Discussing the extrapolation of data from adult CKD studies to fulfil considerable unmet needs in pediatric populations and navigating considerations of ethical approval, informed consent, recruitment, and dosing when enrolling pediatrics into CKD trials with the FDA, GSK, Boehringer Ingelheim and Vertex Pharmaceuticals

Navigating clinical practice guidelines and design more efficient GFR decline studies in an era of growing availability for broad CKD treatments with Otsuka, Bayer and Eli Lilly, and strategically analyzing optimal avenues for reimbursement generation post-approval with AstraZeneca, CSL Vifor and HEOR Ltd

BP2 2

New Speakers for 2024 said:

Nikhil Agrawal

"The agenda is very pertinent to the current needs of CKD drug development with an Impressive lineup of speakers and networking with crucial players in the space.“

Nikhil Agrawal, Global Development Medical Director, AstraZeneca

Houston Gilbert

"I'm excited to connect and interact with collaborators and researchers working at the forefront of bringing novel therapies to patients."

Houston Gilbert, Vice President, Biometrics, HI-BIO

Patrick Schloemer

“I am thrilled to contribute to the 6th CKD Summit and break new ground in the design and analysis of CKD trials. I anticipate a vibrant exchange of novel ideas that will fuel our collaborative quest for advancing therapeutic interventions.”

Patrick Schlömer, Principal Statistician, Bayer